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Abstract
Huntington’s disease (HD) is a hereditary neurodegenerative
condition with no therapeutic intervention known to alter
disease progression, but several trials are ongoing and
biomarkers of disease progression are needed. Tau is an
axonal protein, often altered in neurodegeneration, and recent
studies pointed out its role on HD neuropathology. Our goal
was to study whether cerebrospinal ﬂuid (CSF) tau is a
biomarker of disease progression in HD. After informed
consent, healthy controls, pre-symptomatic and symptomatic
gene expansion carriers were recruited from two HD clinics. All
participants underwent assessment with the Uniﬁed HD Rating
Scale ’99 (UHDRS). CSF was obtained according to a
standardized lumbar puncture protocol. CSF tau was quanti-
ﬁed using enzyme-linked immunosorbent assay. Comparisons
between two groups were tested using ANCOVA. Pearson’s
correlation coefﬁcients were calculated for disease progres-
sion. Signiﬁcance level was deﬁned as p < 0.05. Seventy-six
participants were included in this cross-sectional multicenter
international pilot study. Age-adjusted CSF tau was signiﬁ-
cantly elevated in gene expansion carriers compared with
healthy controls (p = 0.002). UHDRS total functional capacity
was signiﬁcantly correlated with CSF tau (r = 0.29,
p = 0.004) after adjustment for age, and UHDRS total motor
score was signiﬁcantly correlated with CSF tau after adjust-
ment for age (r = 0.32, p = 0.002). Several UHDRS cognitive
tasks were also signiﬁcantly correlated with CST total tau after
age-adjustment. This study conﬁrms that CSF tau concentra-
tions in HD gene mutation carriers are increased compared
with healthy controls and reports for the ﬁrst time that CSF tau
concentration is associated with phenotypic variability in HD.
These conclusions strengthen the case for CSF tau as a
biomarker in HD.
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Huntington’s disease (HD) is a hereditary autosomal dominant
neurodegenerative condition that affects movement control,
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behavior, and cognition (Bates et al. 2015). No therapeutic
intervention has been found to alter disease progression but
several drugs are currently being developed and tested (Bates
et al. 2015). The progression of HD is slow, with half of the
patients surviving at least 24 years after the motor diagnosis
(Rodrigues et al. 2014). This makes studying the efﬁcacy of
disease-modifying compounds challenging.
The development of sensitive biomarkers of disease
progression that reﬂect neuropathology and treatment
response is of vital importance to empower clinical trials.
Tau is a protein with microtubule-stabilizing functions,
which is mainly conﬁned to axons, and when abnormally
assembled or aggregated, is associated with multiple neu-
rodegenerative conditions, Alzheimer’s disease in particular
(Spillantini and Goedert 2013). Indeed, it has been shown
that tau concentration in cerebrospinal ﬂuid (CSF) of patients
with Alzheimer’s disease is associated with disease progres-
sion (Blom et al. 2009). It has been shown that HD patients
have higher CSF total tau concentrations compared with
healthy controls (Constantinescu et al. 2011), but no asso-
ciations with phenotype or independent validation were
made.
Recently, two independent groups showed that human HD,
while principally a ‘huntingtinopathy’, was also in effect a
secondary tauopathy, with tau isoform imbalances, increased
total tau, nuclear tau deposits, and tau co-localization with
mHTT (Fernandez-Nogales et al. 2014; Vuono et al. 2015).
Given all this, we set out to study whether CSF total tau is a
biomarker of disease progression.
Methods
Ethical approval
All human experiments were performed in accordance with the
declaration of Helsinki and approved by the University College
London (UCL)/UCL Hospitals Joint Research Ethics Committee
(UK participants) and the University of British Columbia Clinical
Research Ethics Board, as appropriate. All subjects gave informed
written consent.
Participants
Subjects were recruited from two HD multidisciplinary clinics, one
in London, United Kingdom and other in Vancouver, Canada.
Healthy controls, pre-symptomatic gene expansion carriers, and
symptomatic gene expansion carriers were included. Individual with
infectious, inﬂammatory, or other concomitant CNS disorders or
signiﬁcant comorbidities were excluded. Healthy controls were
deﬁned as individuals without family history of HD and without
symptoms compatible with HD, or without a cytosine-adenine-
guanine (CAG)-expanded allele of the HD gene. Asymptomatic
gene expansion carriers were deﬁned as individuals with a CAG-
expanded allele of the HD gene and with a diagnostic conﬁdence
level inferior to 4. Symptomatic gene expansion carriers were
deﬁned as individuals with a CAG-expanded allele of the HD gene
and with a diagnostic conﬁdence level of 4 (Reilmann et al. 2014).
Clinical assessment
All participants underwent a collection of demographic and clinical
data as well as Uniﬁed HD Rating Scale ’99 (UHDRS) (Hunting-
ton’s disease study group 1996), assessed by an experienced
neurologist. Age, gender, CAG repeat length of gene expansion
carriers, disease stage (Bates et al. 2014), total functional capacity
(Shoulson and Fahn 1979) (TFC), and total motor score (Hunting-
ton’s disease study group 1996) (TMS) were recorded. The UHDRS
cognitive tasks (Symbol-digit modality test, Stroop color matching
task, Stroop word matching task, and Stroop interference task) were
also recorded in the Vancouver cohort (Huntington’s disease study
group 1996). Disease burden was calculated according to CAG
repeat number and age (Penney et al. 1997). Patients with motor
abnormalities were deﬁned as having early, moderate, or advanced
disease using the TFC scale (13–7, early; 6–4, moderate; 3–0,
advanced) assessed by experienced clinical raters (Bates et al.
2014).
CSF sample collection and storage
CSF was obtained by lumbar puncture performed between 9 : 00
and 11 : 00 am after fasting from midnight (water was permitted),
examined by microscopy, and centrifuged to remove cells, and the
acellular portion was frozen at 80°C. Further details were as
previously published (Wild et al. 2015). Hemoglobin concentration
using multiwavelength spectrophotometric readings was assessed to
determine CSF contamination by blood.
CSF total tau quantification
CSF total tau was quantiﬁed using the INNOTEST enzyme-linked
immunosorbent assay according to the manufacturer’s instructions
(Fujirebio, Ghent, Belgium) in one round of experiments using one
batch of reagents by board-certiﬁed laboratory technicians who were
blinded to clinical data.
Statistical analysis
Statistical analysis was performed with Stata version 14 software
(StataCorp, College Station, Texas, USA). Potentially confounding
demographic variables (age and gender) were examined in prelim-
inary analyses. Total tau distribution was tested for normality using
skewness and kurtosis, Shapiro–Wilk and Shapiro–Francia tests.
Comparisons between two groups adjusted for covariates were
tested using ANCOVA. To study the association of total tau with
disease progression, we calculated Pearson’s and partial correlations
coefﬁcients. Bootstrapping with 1000 repetitions was applied to
non-normal variables. Signiﬁcance level was deﬁned as p < 0.05.
Results
We conducted a cross-sectional multicenter international
pilot study of 76 participants (mean age 47.9; standard
deviation [SD] 13.1; range 23–72 years; Table 1). Of these,
24 (31.6%) were healthy controls and 52 (68.4%) were gene
expansion carriers – 13 (17.1%) pre-manifest, 22 (29.0%)
early HD, 6 (7.9%) moderate HD, and 11 (14.5%) advanced
HD. The gene expansion group had a mean CAG repeat
length of 43.8 (SD 3.9, range 36–63), a mean total functional
score (TFC) of 8.6 (SD 4.5, range 0–13), and a Uniﬁed HD
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Rating Score (UHDRS) total motor score (TMS) of 34.6 (SD
29.6, range 0–96). Mean CSF total tau was correlated with
age in healthy controls (r = 0.45, p = 0.006) and with
disease burden score (a product of age and CAG repeat
length) in gene expansion carriers (r = 0.23, p = 0.034). No
difference was found in CSF total tau concentrations between
genders (p = 0.436). Age-adjusted CSF total tau was signif-
icantly elevated in gene expansion carriers compared with
healthy controls (p = 0.002) (Fig. 1a). Total functional
capacity was signiﬁcantly correlated with CSF total tau
(r = 0.29, p = 0.004) after adjustment for age, but not after
adjustment for disease burden(r = 0.21, p = 0.146,
Fig. 1b). UHDRS total motor score was signiﬁcantly corre-
lated with CSF total tau after adjustment for age (r = 0.32,
p = 0.002) and also after adjustment for disease burden score
(r = 0.30, p = 0.025, Fig. 1c). UHDRS symbol-digit modal-
ity test, Stroop color matching task, and Stroop word
matching task were signiﬁcantly correlated with CSF total
tau after adjustment for age (n = 24; r = 0.38, p = 0.020;
r = 0.40, p = 1.335*104; r = 0.40, p = 2.426*104)
and also after adjustment for disease burden score
(r = 0.34, p = 0.008; r = 0.32, p = 0.002; r = 0.32,
p = 0.039). Stroop interference task was not correlated with
CSF total tau (n = 24; r = 0.21, p = 0.147). There was no
association between CSF total tau and CSF hemoglobin
concentration.
Discussion
This study conﬁrms in two independent populations the
previous ﬁnding that CSF total tau concentrations in HD
gene mutation carriers are increased compared with healthy
controls (Constantinescu et al. 2011), and the establishment
of this difference persists after controlling for age – a
possible confounder in the previous report.
To the best of our knowledge, ours is the ﬁrst work where
CSF total tau concentration has been shown to be associated
with phenotypic variability in HD as measured by motor
manifestations and cognitive dysfunction. These associations
persist even after adjustment for disease burden score –
indicating that CSF tau has independent power to predict
clinical phenotype, beyond the known effects of age and
CAG repeat length.
Tau is a microtubule-associated protein, which under
certain pathologic conditions, aggregates abnormally. Still, it
is controversial whether these accumulations are cytotoxic
and cause cellular dysfunction, contributing to neuronal cell
death, or are just an epiphenomenon (Bretteville and Planel
2008). Moreover, while tau expression is particularly high in
neurons with thin unmyelinated axons, this is not speciﬁc to
a particular region or neuronal subpopulation and its
elevation in CSF is considered a non-speciﬁc marker of
neuronal death (Zetterberg et al. 2013).
Table 1 Characteristics of included participants
Group
N
n (%)
Age
mean (SD)
Male
n (%)
CAG
mean (SD)
Burden score
mean (SD)
TFC
mean (SD)
TMS
mean (SD)
Total 76 (100) 47.9 (13.1) 33 (43.4) 43.8 (3.9)* 389.1 (151.8)* 8.6 (4.5)* 34.6 (29.6)*
Healthy controls 24 (31.6) 45.1 (14.3) 8 (33.3) N/A N/A N/A N/A
Pre-manifest HD 13 (17.1) 39.5 (12.5) 6 (46.2) 42.4 (2.5) 255.0 (100.5) 12.6 (0.7) 2.4 (2.7)
Early HD 22 (29.0) 49.3 (10.4) 8 (36.3) 44.1 (2.7) 402.6 (84.9) 10.8 (1.5) 28.3 (15.7)
Moderate HD 6 (7.9) 59.6 (6.2) 5 (83.3) 41.7 (2.7) 365.8 (149.3) 5.0 (0.9) 51.8 (21.1)
Advanced HD 11 (14.5) 54.5 (11.7) 6 (54.5) 46.1 (6.2) 533.4 (179.2) 1.4 (1.4) 75.7 (15.8)
HD, Huntington’s disease; N/A, non-applicable; SD, standard deviation; TFC, UHDRS total functional capacity; TMS, UHDRS total motor score *,
excluding healthy controls.
Fig. 1 (a) Comparison between healthy controls versus gene expan-
sion carriers; (b) Association between total tau and total functional
capacity; (c) Association between total tau and Uniﬁed Huntington’s
Disease Rating Scale total motor score.
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Our ﬁndings strengthen the case for CSF total tau
concentration as a biomarker in HD, reﬂecting neuronal
death and/or secondary tau pathology (Fig. 2). They suggest
the need for longitudinal analysis of CSF total tau to try to
establish its ability to predict disease progression, phenotypic
variability and, eventually, therapeutic response. Further, this
work suggests the need for further investigation of micro-
tubule-associated protein dynamics in HD.
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